Track COSCIENS Biopharma Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

COSCIENS Biopharma Inc. CSCI.TO · Stock Open COSCIENS Biopharma Inc. in new tab

9.60 CAD
EPS
-5.61
P/B
0.45
ROE
-52.83
Beta
1.80
Loading chart...
Key Metrics
Earnings dateNov. 10, 2026
EPS-5.61
Book Value19.92
Price to Book0.45
Debt/Equity13.18
% Insiders27.533%
Growth
Revenue Growth0.30%

DCF valuation

Model fair value for COSCIENS Biopharma Inc. (CSCI.TO)
Result
Sign in to run the valuation for CSCI.TO.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

COSCIENS Biopharma Inc. Logo COSCIENS Biopharma Inc. Analysis (CSCI.TO)

Is COSCIENS Biopharma Inc. a good investment? COSCIENS Biopharma Inc. (CSCI.TO) is currently trading at 9.60 CAD.

Earnings Schedule: COSCIENS Biopharma Inc. is expected to release its next earnings report on Nov. 10, 2026.

Investor FAQ

Does COSCIENS Biopharma Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is COSCIENS Biopharma Inc.?

COSCIENS Biopharma Inc. is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be Nov. 10, 2026. The company currently has a trailing EPS of -5.61.

Company Profile

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. In addition, it focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.

Trades
Dividend History paid per year (CAD)
Historical Dividends
Year Total Dividends
▸1999
0.00 CAD
Aug. 11, 1999 0.0015
May 12, 1999 0.0014
Feb. 10, 1999 0.0014
▸1998
0.01 CAD
Nov. 10, 1998 0.0014
Aug. 12, 1998 0.0014
May 13, 1998 0.0014
Feb. 11, 1998 0.0014
▸1997
0.01 CAD
Nov. 12, 1997 0.0014
Aug. 13, 1997 0.0014
May 13, 1997 0.0013
Feb. 12, 1997 0.0013
▸1996
0.00 CAD
Nov. 13, 1996 0.0003
Stock Splits
Split Date Split Ratio to 1
Oct. 5, 2012 0.17
Nov. 20, 2015 1:100
July 21, 2022 1:25
May 3, 2024 1:4
July 3, 2026 0.33
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion